カテゴリ： GlobalData, ドイツ, 企業調査

Fresenius SE & Co KGaA (FRE)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Fresenius SE & Co KGaA (FRE) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8012950
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月27日
◆ページ数：95
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Fresenius SE & Co KGaA (Fresenius) is a global health care group, which offers products and services for dialysis treatment. It provides various dialysis services through its own clinics and sells its products to other dialysis service providers. Its major products and services includes machines for hemodialysis, acute dialysis and peritoneal dialysis; solutions for infusion therapy; dialysis care services; Spectra laboratories; liver support therapy services; and provision projects and services for hospitals and other health care facilities. It also operates and manages acute care and postacute care hospitals in Germany through Helios Kliniken Group. Its major manufacturing plants are in the US, Germany, China, Sweden and Japan. Fresenius conducts operations in Asia-Pacific, Europe, Africa and the Americas. The company is headquartered in Bad Homburg, Hessen, Germany.

Fresenius SE & Co KGaA (FRE) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2011 to YTD 2017 7
Fresenius SE & Co KGaA, Medical Equipment Deals By Type, 2011 to YTD 2017 8
Fresenius SE & Co KGaA, Medical Equipment, Deals By Region, 2011 to YTD 2017 9
Fresenius SE & Co KGaA, Medical Equipment, Deals By Market, 2011 to YTD 2017 10
Fresenius SE & Co KGaA, Medical Equipment, Deals Summary, 2011 to YTD 2017 11
Fresenius SE & Co KGaA, Medical Equipment, Deal Details 14
Asset Purchase 14
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 14
Fresenius Medical Care Completes Acquisition Of International Dialysis Centers From Euromedic International 15
Fresenius Medical Care Acquires Crit-Line System Assets From Hema Metrics 17
Partnerships 18
Fresenius Medical Care Extends Licensing Agreement with Interface Biologics 18
Debiotech and Fresenius Medical Care Enter into Agreement 19
Verax Biomedical Renews its Commercialization Agreement with Fresenius Kabi USA 20
Sequana Medical Enters into Distribution Agreement with Fresenius Medical Care 21
Toray Industries Enters into Distribution Agreement with Fresenius Medical Care 22
HemaTerra Technologies Enters Into Co-Development Agreement With Fenwal 23
Fenwal Enters Into Co-Marketing Agreement With Applied Science 24
JMS North America Enters Into Distribution Agreement With Fresenius Medical Care For AVF Needles 25
Fenwal Enters Into Co-Marketing Agreement With Biolog-id For RFID Blood Tracking System 26
Fenwal Enters Into Co-Marketing Agreement With Genesis BPS 27
Equity Offering 28
Fresenius Plans Private Placement Of Shares For US$1.3 Billion 28
Debt Offering 29
Fresenius Raises USD530.4 Million in Private Placement of 3% Notes Due 2032 29
Fresenius Raises USD742.5 Million in Private Placement of 2.125% Notes Due 2027 30
Fresenius Raises USD742.5 Million in Private Placement of 0.875% Notes Due 2022 31
Fresenius Raises USD742.5 Million in Private Placement of 1.5% Notes Due 2024 32
Fresenius Raises USD300 Million in Private Placement of Notes 33
Fresenius Medical Care Raises USD400 Million in Private Placement of 4.75% Notes Due 2024 34
Fresenius Medical Care Raises USD500 Million in Private Placement of 4.125% Notes Due 2020 35
Fresenius Medical Care Raises USD518 Million in Private Placement of Convertible Bonds 36
Fresenius Increases Size Of Private Placement Of Notes Due 2024 For US$611.4 Million 37
Fresenius Completes Private Placement Of Notes Due 2019 For US$407.6 Million 38
Fresenius Completes Private Placement Of Notes Due 2021 For US$611.4 Million 39
Fresenius Medical Care Prices Private Placement Of Notes Due 2020 For US$673 Million 40
Fresenius Medical Care Completes Private Placement Of 5.625% Senior Unsecured Notes Due 2019 For US$800 Million 42
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2019 For US$316.4 Million 43
Fresenius Medical Care Completes Private Placement Of 5.875% Senior Unsecured Notes Due 2022 For US$700 Million 44
Fresenius Medical Care Completes Private Placement Of Floating-Rate Senior Notes Due 2016 For US$133.7 Million 45
Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$550 Million 46
Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$400 Million 47
Fresenius Medical Care Completes Private Placement Of 5.75% Senior Unsecured Notes Due 2021 For US$650 Million 48
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2021 For US$403 Million 49
Asset Transactions 50
Fresenius Medical to Divest Dialysis Services Unit in Venezuela 50
Fresenius Medical Care Divests Fresenius Medical care Dialysis Clinic for USD1.4 Million 51
Acquisition 52
Fresenius Medical Care to Acquire NxStage Medical for up to USD2 Billion 52
Fresenius Medical Care Acquires Xenios 54
Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For US$1.1 Billion 55
Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 57
Fresenius Medical Care to Acquire Nefrocontrol 58
Fresenius SE & Co KGaA – Key Competitors 59
Fresenius SE & Co KGaA – Key Employees 60
Fresenius SE & Co KGaA – Locations And Subsidiaries 61
Head Office 61
Other Locations & Subsidiaries 61
Recent Developments 66
Strategy And Business Planning 66
Sep 29, 2017: Fresenius lays cornerstone for new building at headquarters in Bad Homburg 66
Jun 08, 2017: Fresenius Medical Care sees excellent prospects for further growth and launches a new Global Efficiency Program at its Capital Markets Day 2017 68
Mar 20, 2017: Fresenius Helios opens new hospital building in Duisburg 69
Nov 22, 2016: HELIOS lays foundation stone for new hospital building in Wiesbaden 70
Apr 08, 2016: Fresenius Vamed lays foundation stone for new university hospital building 71
Financial Announcements 72
Aug 01, 2017: Fresenius confirms its guidance after a strong second quarter with double-digit sales and earnings growth 72
Oct 27, 2016: Fresenius: Continued strong sales and earnings growth; Lower end of Group earnings guidance raised 75
Aug 01, 2016: Fresenius Medical Care posts accelerated earnings growth in the 2nd quarter 79
May 03, 2016: Strong start into the year – Double-digit earnings growth in constant currency – Fresenius confirms Group guidance for 2016 82
Feb 24, 2016: Outstanding 2015 financial results – 25% dividend increase proposed – Positive outlook for 2016 – New mid-term growth targets 84
Corporate Communications 88
Jul 21, 2017: Fresenius appoints Rachel Empey as Chief Financial Officer 88
Jan 13, 2017: Fresenius Medical Care Announces Leadership Change in North America 89
Jun 26, 2016: Fresenius appoints Stephan Sturm as new Chief Executive Officer – Ulf Mark Schneider leaves the company to pursue another opportunity 90
Legal and Regulatory 91
Jan 31, 2017: Fresenius Medical Care reaches agreement on outstanding payments 91
Jan 26, 2017: U.S. District Court Issues Preliminary Injunction Against Premium Assistance Regulation 92
Other Significant Developments 93
Jul 12, 2017: Fresenius Medical Care successfully amends and extends its credit agreement, ahead of schedule 93
Aug 17, 2016: Fresenius Kabi investing nearly $250 million to expand plant near Chicago 94
Appendix 95
Methodology 95
About GlobalData 95
Contact Us 95
Disclaimer 95

List of Tables
Fresenius SE & Co KGaA, Medical Equipment, Key Facts, 2016 2
Fresenius SE & Co KGaA, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2011 to YTD 2017 7
Fresenius SE & Co KGaA, Medical Equipment Deals By Type, 2011 to YTD 2017 8
Fresenius SE & Co KGaA, Medical Equipment, Deals By Region, 2011 to YTD 2017 9
Fresenius SE & Co KGaA, Deals By Market, 2011 to YTD 2017 10
Fresenius SE & Co KGaA, Medical Equipment, Deals Summary, 2011 to YTD 2017 11
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 14
Fresenius Medical Care Completes Acquisition Of International Dialysis Centers From Euromedic International 15
Fresenius Medical Care Acquires Crit-Line System Assets From Hema Metrics 17
Fresenius Medical Care Extends Licensing Agreement with Interface Biologics 18
Debiotech and Fresenius Medical Care Enter into Agreement 19
Verax Biomedical Renews its Commercialization Agreement with Fresenius Kabi USA 20
Sequana Medical Enters into Distribution Agreement with Fresenius Medical Care 21
Toray Industries Enters into Distribution Agreement with Fresenius Medical Care 22
HemaTerra Technologies Enters Into Co-Development Agreement With Fenwal 23
Fenwal Enters Into Co-Marketing Agreement With Applied Science 24
JMS North America Enters Into Distribution Agreement With Fresenius Medical Care For AVF Needles 25
Fenwal Enters Into Co-Marketing Agreement With Biolog-id For RFID Blood Tracking System 26
Fenwal Enters Into Co-Marketing Agreement With Genesis BPS 27
Fresenius Plans Private Placement Of Shares For US$1.3 Billion 28
Fresenius Raises USD530.4 Million in Private Placement of 3% Notes Due 2032 29
Fresenius Raises USD742.5 Million in Private Placement of 2.125% Notes Due 2027 30
Fresenius Raises USD742.5 Million in Private Placement of 0.875% Notes Due 2022 31
Fresenius Raises USD742.5 Million in Private Placement of 1.5% Notes Due 2024 32
Fresenius Raises USD300 Million in Private Placement of Notes 33
Fresenius Medical Care Raises USD400 Million in Private Placement of 4.75% Notes Due 2024 34
Fresenius Medical Care Raises USD500 Million in Private Placement of 4.125% Notes Due 2020 35
Fresenius Medical Care Raises USD518 Million in Private Placement of Convertible Bonds 36
Fresenius Increases Size Of Private Placement Of Notes Due 2024 For US$611.4 Million 37
Fresenius Completes Private Placement Of Notes Due 2019 For US$407.6 Million 38
Fresenius Completes Private Placement Of Notes Due 2021 For US$611.4 Million 39
Fresenius Medical Care Prices Private Placement Of Notes Due 2020 For US$673 Million 40
Fresenius Medical Care Completes Private Placement Of 5.625% Senior Unsecured Notes Due 2019 For US$800 Million 42
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2019 For US$316.4 Million 43
Fresenius Medical Care Completes Private Placement Of 5.875% Senior Unsecured Notes Due 2022 For US$700 Million 44
Fresenius Medical Care Completes Private Placement Of Floating-Rate Senior Notes Due 2016 For US$133.7 Million 45
Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$550 Million 46
Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$400 Million 47
Fresenius Medical Care Completes Private Placement Of 5.75% Senior Unsecured Notes Due 2021 For US$650 Million 48
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2021 For US$403 Million 49
Fresenius Medical to Divest Dialysis Services Unit in Venezuela 50
Fresenius Medical Care Divests Fresenius Medical care Dialysis Clinic for USD1.4 Million 51
Fresenius Medical Care to Acquire NxStage Medical for up to USD2 Billion 52
Fresenius Medical Care Acquires Xenios 54
Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For US$1.1 Billion 55
Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 57
Fresenius Medical Care to Acquire Nefrocontrol 58
Fresenius SE & Co KGaA, Key Competitors 59
Fresenius SE & Co KGaA, Key Employees 60
Fresenius SE & Co KGaA, Other Locations 61
Fresenius SE & Co KGaA, Subsidiaries 61

★海外企業調査レポート[Fresenius SE & Co KGaA (FRE)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Currence Holding B.V.
    Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report Summary Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • CIRCOR Aerospace Products Group：企業の戦略・SWOT・財務情報
    CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report Summary CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Reins International Inc.：企業の戦略・SWOT・財務分析
    Reins International Inc. - Strategy, SWOT and Corporate Finance Report Summary Reins International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • CellSeed Inc (7776)：企業の財務・戦略的SWOT分析
    Summary CellSeed Inc (CellSeed) is a developer of regenerative medicine. The company’s products include epithelial cell sheet for corneal regeneration, regenerated cardiac patch, epithelial cell sheet for esophageal regeneration, cell sheet for periodontal tissue regeneration and regenerated cartila …
  • VERBIO Vereinigte BioEnergie AG (VBK)：企業の財務・戦略的SWOT分析
    VERBIO Vereinigte BioEnergie AG (VBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • China Resources Gas Group Ltd (1193)：石油・ガス：M&Aディール及び事業提携情報
    Summary China Resources Gas Group Ltd (CR Gas), a subsidiary of China Resources (Holdings) Co Ltd, is a gas company that offers distribution of natural gas and petroleum gas. The company provides downstream city gas distribution business including piped natural gas distribution and natural gas filli …
  • PositiveID Corp (PSID)-医療機器分野：企業M&A・提携分析
    Summary PositiveID Corp (PositiveID) is a medical device company that develops biological detection and molecular diagnostic systems. The company develops microfluidic systems for automated preparation and performance of biological assays. Its products include firefly Dx and m-band. PositiveID’s tec …
  • Attica Bank S.A.：企業の戦略・SWOT・財務分析
    Attica Bank S.A. - Strategy, SWOT and Corporate Finance Report Summary Attica Bank S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Tohoku Electric Power Co Inc (9506)：企業の財務・戦略的SWOT分析
    Tohoku Electric Power Co Inc (9506) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Advaxis Inc (ADXS)：企業の財務・戦略的SWOT分析
    Advaxis Inc (ADXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Delphi Financial Group, Inc.：企業の戦略・SWOT・財務情報
    Delphi Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Delphi Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • GlycoNex Inc (4168)-製薬・医療分野：企業M&A・提携分析
    Summary GlycoNex Inc (GlycoNex) is a drug discovery company that conducts research and development in glycosphingolipid antigen and human monoclonal antibody technologies to develop cancer drugs. The company carries out antibody drug development through various technology platforms such as glycosphi …
  • Origin Energy Limited：戦略・SWOT・企業財務分析
    Origin Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Origin Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The Restaurant Group Plc：企業の戦略・SWOT・財務情報
    The Restaurant Group Plc - Strategy, SWOT and Corporate Finance Report Summary The Restaurant Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Columbus Energy Resources PLC (CERP)：石油・ガス：M&Aディール及び事業提携情報
    Summary Columbus Energy Resources PLC (Columbus Energy), formerly LGO Energy Plc is an oil and gas exploration and development company. The company acquires, explores, develops and produces oil and gas properties. It operates oil and gas assets in Trinidad including the South West Peninsula licenses …
  • Caverion Corp：企業の戦略・SWOT・財務情報
    Caverion Corp - Strategy, SWOT and Corporate Finance Report Summary Caverion Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • China Southern Power Grid Co Ltd：電力：M&Aディール及び事業提携情報
    Summary China Southern Power Grid Co Ltd (CSG) is a power company that invests in construction, operations and management of the power grids. The company concentrates on developing regional power network, managing power dispatching and transaction center, administering regional power market, and dis …
  • Santen Pharmaceutical Co Ltd (4536)：医療機器：M&Aディール及び事業提携情報
    Summary Santen Pharmaceutical Co Ltd (Santen) focuses on the research, development, manufacture and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for bacterial conjunctivitis, glaucoma, dry eye, Inflammation and others; OTC …
  • BioMotiv LLC-製薬・医療分野：企業M&A・提携分析
    Summary BioMotiv LLC (BioMotiv) is a development company specializes in the licensing and development of therapeutics across wide disease areas including proteins, small molecules, antibodies, and nucleotides. The company in association with The Harrington Project for Discovery & Development acceler …
  • Ck Hutchison Holdings Ltd：企業の戦略・SWOT・財務分析
    Ck Hutchison Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Ck Hutchison Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆